Update in the latest heparin investigation...FDA went to the wrong place...BD
U.S. health officials evaluated the wrong factory when assessing the safety of a Chinese-made drug ingredient that may be a source of problems with a blood thinner, the Food and Drug Administration said Monday.
Baxter International's heparin has been linked to four deaths and hundreds of reports of allergic reactions. An investigation will take FDA inspectors to China this week. Inspections are under way at a Baxter facility in Cherry Hill, N.J. facility and at company supplier Scientific Protein Laboratories of Waunakee, Wis.